Oncology Drugs - Brazil

Brazil

The Oncology Drugs market in Brazil is expected to witness a significant growth in revenue, reaching a projected value of R €3.24bn by 2024.
This growth is anticipated to continue at a steady pace, with an annual growth rate (CAGR 2024-2029) of 7.35%.
As a result, the market volume is forecasted to reach R €4.62bn by 2029.
When compared globally, it is noteworthy that United States is expected to generate the highest revenue in the Oncology Drugs market, with a staggering amount of €96,360.00m in 2024.
Brazil is experiencing a surge in the demand for innovative oncology drugs, driven by a growing middle class and increased investment in healthcare infrastructure.

Key regions: France, Europe, United Kingdom, Brazil, India

Marché

Région

Comparaison de régions

Monnaie

Analyst Opinion

The demand for oncology drugs in Brazil has been steadily increasing over the years due to various factors.

Customer preferences: Patients in Brazil have shown a preference for targeted therapies over traditional chemotherapy due to the former's ability to specifically target cancer cells while minimizing damage to healthy cells. Additionally, there has been an increase in demand for immunotherapies, which stimulate the body's immune system to fight cancer.

Trends in the market: The oncology drugs market in Brazil has been experiencing a shift towards personalized medicine, with the development of drugs that are tailored to specific genetic mutations. This has led to an increase in the number of clinical trials being conducted in Brazil, as pharmaceutical companies seek to develop new targeted therapies. Furthermore, there has been a rise in the use of biosimilars, which are cheaper versions of biologic drugs that have already been approved.

Local special circumstances: Brazil has a universal healthcare system, which has led to a greater demand for affordable oncology drugs. The government has implemented policies to increase access to these drugs, such as the "Farmácia Popular" program, which provides free or subsidized medication to low-income individuals. Additionally, the Brazilian regulatory agency ANVISA has streamlined the drug approval process, making it easier for pharmaceutical companies to bring new drugs to market.

Underlying macroeconomic factors: The Brazilian economy has been experiencing a period of recovery, with GDP growth expected to increase in the coming years. This has led to an increase in healthcare spending, which has benefited the oncology drugs market. However, the devaluation of the Brazilian real has made imported drugs more expensive, which could potentially limit the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.